FDA approves at-home use of BioXcel's agitation drug Igalmi
The FDA approved at-home use of BioXcel Therapeutics' Igalmi (dexmedetomidine) for agitation associated with schizophrenia or bipolar disorder, expanding access beyond clinical settings.
·2 sources